In a bid to highlight oncology, Novartis has split its pharmaceuticals division into two new business units, one of which will be devoted exclusively to cancer medicines including cell and gene therapies. Bruno Strigini will head the new unit, reporting directly to Joseph Jimenez, the chief executive.
